Efficacy of Liposomal Bupivacaine Versus 0.25% Bupivacaine for Laparoscopic Urologic Surgery
NCT ID: NCT02222129
Last Updated: 2015-04-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
206 participants
INTERVENTIONAL
2012-12-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures
NCT02805504
PAIN - Postoperative Analgesia INvestigation
NCT02111746
Liposomal vs. Conventional Bupivacaine for Pain Control
NCT06231355
Subcostal TAP Block With Liposomal Bupivacaine Versus Bupivacaine in Donor Nephrectomy Patients: A Prospective Study
NCT02287623
Liposomal Bupivacaine Versus Ropivacaine for Preperitoneal Infiltration Analgesia in Upper Abdominal Laparotomy
NCT07271979
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bupivacaine
Surgical site infiltration of 0.25% bupivacaine.
Bupivacaine
Liposomal bupivacaine
Surgical site infiltration of liposomal bupivacaine.
liposomal bupivacaine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bupivacaine
liposomal bupivacaine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Allergy to bupivacaine.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Knight, Richard, M.D.
INDIV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard B Knight, MD
Role: PRINCIPAL_INVESTIGATOR
San Antonio Uniformed Services Health Education Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baptist Health System
San Antonio, Texas, United States
Methodist Healthcare System
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BHS120036
Identifier Type: OTHER
Identifier Source: secondary_id
403263-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.